Concepedia

Alan Swaisland

AS

13

Publications

2.2K

Citations

13

H-Index

1973

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

Institute of Cancer Research

AstraZeneca (Brazil)

AstraZeneca (United States)

University of Ulster

Alan Swaisland is an author at AstraZeneca (United Kingdom) specializing in medicine, organic chemistry, and pharmacology.

Top concepts

Publications per year

1973–2011

13

Publications

13

Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide

Peter Sims, P.L. Grover, Alan Swaisland et al. · Nature · 1974 · 1.1K citations

, , +3

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra et al. · Journal of Clinical Oncology · 2009 · 379 citations

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh et al. · Clinical Cancer Research · 2006 · 191 citations

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

R.A. Hannon, Glen Clack, Martin Rimmer et al. · Journal of Bone and Mineral Research · 2009 · 110 citations · Full text

, , +16

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

José Baselga, Andrés Cervantes, Erika Martinelli et al. · Clinical Cancer Research · 2010 · 108 citations

Rows per page

1–5 of 13